The rise of a new class of weight-loss medications is starting to show up on restaurant menus, not just in doctors' offices.
Chipotle, McDonald's, and Shake Shack are among the restaurant chains revamping their menus as more consumers go on weight-loss drugs, according to CBS News. These medications, often referred to by brand names like Ozempic and Wegovy, belong to a class known as GLP-1 receptor agonists. They work by suppressing appetite and slowing digestion, and they have been adopted by a rapidly growing share of the population over the past few years, first largely for diabetes management and increasingly for weight loss specifically.
That shift in appetite and eating habits has real consequences for an industry built around volume and indulgence. Restaurant chains have been experimenting with smaller portions, higher-protein options, and menu items designed to appeal to customers who eat less per visit but may still want quality and variety. Getting this balance right matters for chains that depend on frequent visits and predictable order sizes to plan everything from staffing levels to ingredient supply chains and pricing strategy.
The trend adds to a broader set of adjustments the restaurant industry has been making in recent years, alongside inflation-driven pricing changes and shifts in consumer habits around convenience, value, and health consciousness. Fast food and fast casual chains in particular have faced pressure to demonstrate they can offer both indulgent options and lighter, protein-forward alternatives within the same menu, a balancing act that has become more urgent as the share of the population using these medications keeps climbing.
Chains that adapt their menus effectively may find a new way to retain customers whose relationship with food is changing, while those slower to adjust risk losing visits to competitors that do. Analysts have increasingly flagged the GLP-1 trend as a factor worth watching across the consumer and restaurant sectors, alongside more traditional drivers like pricing and traffic.
Expect more chains to announce menu changes and smaller-portion options as the use of weight-loss medications continues to grow.
Why are restaurants responding to weight-loss drugs?
As more consumers take appetite-suppressing medications, their eating habits and portion preferences are changing, prompting chains to adjust menus to match.
Which chains are making changes?
Chipotle, McDonald's, and Shake Shack are among the chains reported to be revamping their menus.